Celgene RV-AML-PI - 0759: Sequential Treatment with Azacitidine and Lenalidomide for Relapsed and Refractory Patients with Acute Myeloid Leukemia

Objective

This is a Phase 2 clinical study investigating the sequential use of azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia

IRB Protocol Number

12-1283

Principal Investigator(s)

DAN POLLYEA

Cancer Trials

• Leukemia/Myelodysplasia

Sponsor(s)

UCCC

Contact

LEIGH WALZER at 720-848-0736
or LEIGH.WALZER@UCDENVER.EDU

Eligibility and Other Participant Information

What To Expect : The amount of time you participate in this study will depend on how your disease responds and how you tolerate the treatment. After you stop study treatment, you will be asked to come to the clinic for a final visit. // Eligibility includes but is not limited to patients 18 years of age or older with relapsed and refractory acute myeloid leukemia